Mergers and acquisitions

Biogen head office
#Apellis Pharmaceuticals #Biogen #Mergers and acquisitions

Biogen grows immunology and rare disease portfolio with Apellis buyout

Biogen has revealed it will acquire Apellis Pharmaceuticals for an upfront payment of approximately $5.6 billion and a contingent value right (CVR) per share payable upon achievement of certain thresholds.  Apellis stockholders will receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being… Read More

#Business & Investment #News

#AstraZeneca #Cell therapy #EsoBiotec #Mergers and acquisitions #Oncology

AstraZeneca buys in vivo cell therapy specialists EsoBiotec

AstraZeneca has revealed it will acquire EsoBiotec for a total consideration of up to $1 billion.  The acquisition includes the company’s Engineered NanoBody Lentiviral (ENaBL) platform, which empowers the immune system to attack cancers.  ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T… Read More

#Business & Investment #News

T cells
#Autoimmune disease #Gilead Sciences #Mergers and acquisitions #T cell engagers

Gilead to advance first T cell engager for autoimmune diseases

Gilead Sciences has entered an agreement to acquire Ouro Medicines, a biotechnology company focused on developing T cell engager therapies for autoimmune diseases.  The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead’s inflammation portfolio.   OM336 is designed to enable rapid and deep B cell depletion following… Read More

#Business & Investment #News

Novartis head office
#Mergers and acquisitions #Novartis #Oncology #Solid tumours #Synnovation Therapeutics

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion

Novartis has agreed a deal with Synnovation Therapeutics to acquire Pikavation Therapeutics and its portfolio of PI3Kα inhibitor programmes, including SNV4818.  Pikavation is a wholly-owned subsidiary of Synnovation.  SNV4818 is a potentially best-in-class pan-mutant selective PI3Kα inhibitor currently in Phase I/II clinical trials for the treatment of HR+/HER2- metastatic breast… Read More

#Business & Investment #News

#Celyn Therapeutics #Kairos Pharma #Lung cancer #Mergers and acquisitions #Oncology

Kairos acquires AI‑designed pan‑EGFR inhibitor from Celyn

Kairos Pharma has entered into binding terms to acquire CL-273, an investigational, reversible, wild-type-sparing pan‑EGFR small‑molecule inhibitor, from Celyn Therapeutics.  CL-273 was discovered using a proprietary AI-driven drug discovery platform. It targets the resistant mutations that develop when using EGFR tyrosine kinase inhibitors, thereby reversing resistance.   It is specifically engineered… Read More

#Business & Investment #News

#GSK #Hypertension #Mergers and acquisitions

GSK buys 35Pharma for pulmonary hypertension treatment

GSK will pay $950 million for Canadian biopharmaceutical company 35Pharma, specialised in the development of novel protein-based therapeutics.  The acquisition includes HS235, a potential best-in-class investigational medicine that has completed Phase I healthy volunteer clinical trials, with studies to start imminently in pulmonary arterial hypertension (PAH) and pulmonary hypertension due… Read More

#Business & Investment #News

Gilead offices
#Advanced Therapies #Arcellx #CAR-T #Cell therapy #Gilead Sciences #Mergers and acquisitions

Gilead Sciences to acquire CAR-T company Arcellx

Gilead Sciences has entered into a definitive agreement to acquire Arcellx for an equity value of $7.8 billion.   Arcellx is a biotechnology company focused on delivering a new class of immunotherapies for patients with cancer and other incurable diseases.  The companies have an existing collaboration to co-develop and co-commercialise Arcellx’s… Read More

#Business & Investment #News #Trending News

#AI / data analytics / healthtech / informatics #Antibodies #Biotech #Drug discovery #GLP-1 #IPO #Mergers and acquisitions #Neuroscience

JPM 2026: Less talk and more action 

‘JPM 2026’ certainly felt different to recent editions of the conference. The sky was blue – and the XBI had nearly doubled over the previous nine months.  There’s nothing like a little winter sun and booming stocks to put a spring in an executive’s step!  But questions over the robustness of the biopharma sector remain – to be expected after… Read More

#Exclusive Content

GSK offices
#Allergy #GSK #Mergers and acquisitions #Monoclonal antibodies #RAPT Therapeutics

GSK expands food allergy pipeline with RAPT purchase

GSK has entered a definitive agreement to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for inflammatory and immunologic diseases.   The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens.  Under the terms of the… Read More

#Business & Investment #News

Lilly Biotechnology Center
#Acute inflammatory conditions #Cardiometabolic diseases #Eli Lilly #Mergers and acquisitions #Neurodegenerative disorders #Ventyx Biosciences

Lilly acquires Ventyx Biosciences for $1.2 billion

Eli Lilly has agreed to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on developing oral therapies for patients with inflammatory-mediated diseases.  Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across a broad range of disease states with high unmet need.   These… Read More

#Business & Investment #News

Leukaemia
#Amgen #Haematology #Mergers and acquisitions #Oncology

Amgen acquires Dark Blue Therapeutics for $840 million

Oncology biotech Dark Blue Therapeutics has been acquired by Amgen for up to $840 million, including upfront and future milestones.  Dark Blue's lead candidate DBT 3757, currently in IND-enabling studies, represents a first-in-class therapeutic strategy for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), with the potential for producing… Read More

#Business & Investment #News

#Biopharma #Evaluate Pharma #Merck #Mergers and acquisitions #Oncology

M&A boosted biopharma by $36bn at end of 2025, report finds 

A surge in mergers and acquisitions (M&A) boosted the biopharma market by $36 billion at the end of 2025, a new report finds.  Evaluate’s 2026 Preview Report shows $36 billion was generated through M&A last October and November, largely through biotech buyout. The report predicts M&A will continue to play an important role in the… Read More

#Business & Investment #News

#Antibodies #Genmab #Mergers and acquisitions #Oncology

Genmab closes its $8 billion acquisition of Merus

Genmab has announced that the conditions to acquire all the issued and outstanding common shares of Merus for $97 per common share in cash have been satisfied.   The company says the transaction diversifies its revenue and will drive sustained growth into the next decade.  With the acquisition, Genmab adds petosemtamab… Read More

#Business & Investment #News

#GLP-1 #Mergers and acquisitions #Pfizer #Weight loss

Pfizer boosts weight loss pipeline with GLP-1 drug

Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of ShangAhai Fosun Pharmaceutical, for the development, manufacturing and commercialisation of YP05002.  YP05002 is a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase I development for chronic weight management.  “We look forward… Read More

#Business & Investment #News

Prostate cancer cells
#Gilead Sciences #Mergers and acquisitions #Oncology #Sprint Bioscience

Gilead buys Sprint Bioscience’s TREX1 cancer programme

Gilead Sciences has acquired the TREX1 cancer programme from Sprint Bioscience for an upfront payment of $14 million plus milestone payments up to $400 million.  The objective of the TREX1 programme, which is in the preclinical phase, is to develop drugs that inhibit the TREX1 protein in order to enhance… Read More

#Business & Investment #News

Johnson & Johnson head office
#Johnson & Johnson #Mergers and acquisitions #Oncology #Prostate cancer

Oncology company Halda acquired by Johnson & Johnson

Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion, payable in cash at closing, subject to customary adjustments.  Halda’s portfolio includes HLD-0915, a first-in-class, oral Regulated Induced Proximity Targeting Chimeras (RIPTAC) therapeutic, in development for metastatic castration-resistant prostate cancer (mCRPC).  HLD-0915 is an innovative bifunctional small molecule therapy designed… Read More

#Business & Investment #News